Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis-Reference-Cited by-同舟云学术

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Published:2017-04-25 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Filippini Graziella¹,Del Giovane Cinzia²,Clerico Marinella³,Beiki Omid⁴⁵,Mattoscio Miriam⁶,Piazza Federico³,Fredrikson Sten⁴,Tramacere Irene¹,Scalfari Antonio⁶,Salanti Georgia⁷

Affiliation:

1. Fondazione IRCCS, Istituto Neurologico Carlo Besta; Scientific Direction; via Celoria, 11 Milan Italy 20133

2. University of Modena and Reggio Emilia; Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine; Via del Pozzo 71 Modena Italy 41124

3. AOU San Luigi Gonzaga; University of Turin, Division of Neurology; Regione Gonzole, 13 Orbassano Torino Italy 10043

4. Karolinska Institutet; Department of Clinical Neuroscience; Stockholm Sweden 17177

5. Kermanshah University of Medical Sciences; Department of Epidemiology and Biostatistics; Kermanshah Iran

6. Imperial College London; Department of Medicine, Division of Brain Sciences, Centre for Neuroscience, Wolfson Neuroscience Laboratories; Du Cane Road London UK W12 0NN

7. University of Bern; Institute of Social and Preventive Medicine (ISPM); Finkenhubelweg 11 Bern Switzerland 3005

Publisher

Wiley

Subject

Pharmacology (medical)

Reference129 articles.

1. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial;Achiron;Archives of Neurology,2004

2. Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS);Fazekas;European Journal of Neurology,2010

3. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes;Kappos;Neurology,2006

4. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study;Kappos;Lancet,2007

5. Long-term effect of early treatment with interferon beta-1bafter a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial;Kappos;Lancet Neurology,2009

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis;Frontiers in Cellular Neuroscience;2024-08-05

2. Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations;Therapeutic Advances in Neurological Disorders;2024-01

3. Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study;The Lancet Regional Health - Americas;2024-01

4. Multiple sclerosis disease-modifying drug use by immigrants: a real-world study;Scientific Reports;2023-12-01

5. Chimeric CNS-targeting-peptide engineered exosomes for experimental autoimmune encephalomyelitis therapy;International Immunopharmacology;2023-11